| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Biochemistry and Molecular Biology [M. L. G., C. M. B., E. H. Y., J. M. G., J. F. F., G. J. W., P. A. J., J. W. F.], Institute for Genetic Medicine [E. H. Y., J. M. G., J. F. F., G. J. W., J. W. F.], University of Southern California, School of Medicine, Los Angeles, California 90033, and Queensland Institute of Medical Research, Brisbane 4029, Australia [G. J. W., N. K. H.]
Methylation of the 5' CpG island of the p16 tumor suppressor gene represents one possible mechanism for inactivation of this cell cycle regulatory gene that is also a melanoma predisposition locus. We have investigated the potential contribution of somatic silencing of the p16 gene by DNA methylation in 30 cases of sporadic cutaneous melanoma. The methylation status of the 5' CpG island of p16 was initially determined by Southern analysis and then reevaluated (in a blinded manner) using methylation-specific PCR, methylation-sensitive single nucleotide primer extension, and bisulfite genomic sequencing. All methodologies yielded concordant results, and significant levels of methylation were observed in 3 of the 30 (10%) melanoma DNAs analyzed. Of the three tumors found to be methylated, two were also positive for LOH on 9p21 (where the p16 gene resides), implying that both p16 alleles were inactivated, one via deletion and the other via methylation-associated transcriptional silencing. The association between methylation and transcriptional silencing of p16 was also further supported by inducing p16 expression with a DNA demethylating agent (5-aza-2'-deoxycytidine) in a melanoma cell line known to harbor a methylated p16 allele. Although methylation-associated gene silencing does not represent a common mechanism for p16 inactivation in sporadic melanoma, our findings provide support that PCR-based techniques, such as methylation-specific PCR and methylation-sensitive single nucleotide primer extension, can be reliably used for the accurate detection and quantitation of aberrant levels of DNA methylation in tumor specimens.
1 This work was supported in part by Grant R01CA66021 (to J. W. F.) and USPHS Grant R35CA49758 (to P. A. J.) from the National Cancer Institute.
2 To whom requests for reprints should be addressed, at Department of Biochemistry and Molecular Biology, Institute for Genetic Medicine, University of Southern California, 2250 Alcazar Street, IGM240, Los Angeles, CA 90033.
Received 8/ 1/97. Accepted 10/ 3/97.
This article has been cited by other articles:
![]() |
D. E. Freedberg, S. H. Rigas, J. Russak, W. Gai, M. Kaplow, I. Osman, F. Turner, J. A. Randerson-Moor, A. Houghton, K. Busam, et al. Frequent p16-Independent Inactivation of p14ARF in Human Melanoma J Natl Cancer Inst, June 4, 2008; 100(11): 784 - 795. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Muthusamy, S. Duraisamy, C. M. Bradbury, C. Hobbs, D. P. Curley, B. Nelson, and M. Bosenberg Epigenetic Silencing of Novel Tumor Suppressors in Malignant Melanoma Cancer Res., December 1, 2006; 66(23): 11187 - 11193. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Taback, S. J. O'Day, P. D. Boasberg, S. Shu, P. Fournier, R. Elashoff, H.-J. Wang, and D. S. B. Hoon Circulating DNA Microsatellites: Molecular Determinants of Response to Biochemotherapy in Patients With Metastatic Melanoma J Natl Cancer Inst, January 21, 2004; 96(2): 152 - 156. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Segura-Pacheco, C. Trejo-Becerril, E. Perez-Cardenas, L. Taja-Chayeb, I. Mariscal, A. Chavez, C. Acuna, A. M. Salazar, M. Lizano, and A. Duenas-Gonzalez Reactivation of Tumor Suppressor Genes by the Cardiovascular Drugs Hydralazine and Procainamide and Their Potential Use in Cancer Therapy Clin. Cancer Res., May 1, 2003; 9(5): 1596 - 1603. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Recio, F. P. Noonan, H. Takayama, M. R. Anver, P. Duray, W. L. Rush, G. Lindner, E. C. De Fabo, R. A. DePinho, and G. Merlino Ink4a/Arf Deficiency Promotes Ultraviolet Radiation-induced Melanomagenesis Cancer Res., November 15, 2002; 62(22): 6724 - 6730. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Daskalakis, T. T. Nguyen, C. Nguyen, P. Guldberg, G. Kohler, P. Wijermans, P. A. Jones, and M. Lubbert Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment Blood, September 26, 2002; 100(8): 2957 - 2964. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Edmunds, D. P. Kelsell, J. L. Hungerford, and I. A. Cree Mutational Analysis of Selected Genes in the TGF{beta}, Wnt, pRb, and p53 Pathways in Primary Uveal Melanoma Invest. Ophthalmol. Vis. Sci., September 1, 2002; 43(9): 2845 - 2851. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. M. J. van den Aardweg, N. C. Naus, A. C. A. Verhoeven, A. de Klein, and G. P. M. Luyten Cellular Radiosensitivity of Primary and Metastatic Human Uveal Melanoma Cell Lines Invest. Ophthalmol. Vis. Sci., August 1, 2002; 43(8): 2561 - 2565. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Straume, J. Smeds, R. Kumar, K. Hemminki, and L. A. Akslen Significant Impact of Promoter Hypermethylation and the 540 C>T Polymorphism of CDKN2A in Cutaneous Melanoma of the Vertical Growth Phase Am. J. Pathol., July 1, 2002; 161(1): 229 - 237. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Widschwendter and P. A. Jones The Potential Prognostic, Predictive, and Therapeutic Values of DNA Methylation in Cancer : Commentary re: J. Kwong et al., Promoter Hypermethylation of Multiple Genes in Nasopharyngeal Carcinoma. Clin. Cancer Res., 8: 131-137, 2002, and H-Z. Zou et al., Detection of Aberrant p16 Methylation in the Serum of Colorectal Cancer Patients. Clin. Cancer Res., 8: 188-191, 2002. Clin. Cancer Res., January 1, 2002; 8(1): 17 - 21. [Full Text] [PDF] |
||||
![]() |
I. D.C. Markl, J. Cheng, G. Liang, D. Shibata, P. W. Laird, and P. A. Jones Global and Gene-specific Epigenetic Patterns in Human Bladder Cancer Genomes Are Relatively Stable in Vivo and in Vitro over Time Cancer Res., August 1, 2001; 61(15): 5875 - 5884. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Esteller, P. G. Corn, S. B. Baylin, and J. G. Herman A Gene Hypermethylation Profile of Human Cancer Cancer Res., April 1, 2001; 61(8): 3225 - 3229. [Abstract] [Full Text] |
||||
![]() |
P. M. Pollock, J. Welch, and N. K. Hayward Evidence for Three Tumor Suppressor Loci on Chromosome 9p Involved in Melanoma Development Cancer Res., February 1, 2001; 61(3): 1154 - 1161. [Abstract] [Full Text] |
||||
![]() |
O. Straume, L. Sviland, and L. A. Akslen Loss of Nuclear p16 Protein Expression Correlates with Increased Tumor Cell Proliferation (Ki-67) and Poor Prognosis in Patients with Vertical Growth Phase Melanoma Clin. Cancer Res., May 1, 2000; 6(5): 1845 - 1853. [Abstract] [Full Text] |
||||
![]() |
C. A. Eads, K. D. Danenberg, K. Kawakami, L. B. Saltz, C. Blake, D. Shibata, P. V. Danenberg, and P. W. Laird MethyLight: a high-throughput assay to measure DNA methylation Nucleic Acids Res., April 15, 2000; 28(8): e32 - e. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Tamura, J. Yin, S. Wang, A. S. Fleisher, T. Zou, J. M. Abraham, D. Kong, K. N. Smolinski, K. T. Wilson, S. P. James, et al. E-Cadherin Gene Promoter Hypermethylation in Primary Human Gastric Carcinomas J Natl Cancer Inst, April 5, 2000; 92(7): 569 - 573. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kazianis, L. D. Coletta, D. C. Morizot, D. A. Johnston, E. A. Osterndorff, and R. S. Nairn Overexpression of a fish CDKN2 gene in a hereditary melanoma model Carcinogenesis, April 1, 2000; 21(4): 599 - 605. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Katzenellenbogen, S. B. Baylin, and J. G. Herman Hypermethylation of the DAP-Kinase CpG Island Is a Common Alteration in B-Cell Malignancies Blood, June 15, 1999; 93(12): 4347 - 4353. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. K. Wiencke, S. Zheng, A. Lafuente, M. J. Lafuente, C. Grudzen, M. R. Wrensch, R. Miike, A. Ballesta, and M. Trias Aberrant Methylation of p16INK4a in Anatomic and Gender-specific Subtypes of Sporadic Colorectal Cancer Cancer Epidemiol. Biomarkers Prev., June 1, 1999; 8(6): 501 - 506. [Abstract] [Full Text] |
||||
![]() |
L. E. Lantry, Z. Zhang, K. A. Crist, Y. Wang, G. J. Kelloff, R. A. Lubet, and M. You 5-Aza-2'-deoxycytidine is chemopreventive in a 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone-induced primary mouse lung tumor model Carcinogenesis, February 1, 1999; 20(2): 343 - 346. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Aggerholm, P. Guldberg, M. Hokland, and P. Hokland Extensive Intra- and Interindividual Heterogeneity of p15INK4B Methylation in Acute Myeloid Leukemia Cancer Res., January 1, 1999; 59(2): 436 - 441. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Chin, G. Merlino, and R. A. DePinho Malignant melanoma: modern black plague and genetic black box Genes & Dev., November 15, 1998; 12(22): 3467 - 3481. [Full Text] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |